211 related articles for article (PubMed ID: 33879799)
1. RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways.
Gudiño V; Pohl SÖ; Billard CV; Cammareri P; Bolado A; Aitken S; Stevenson D; Hall AE; Agostino M; Cassidy J; Nixon C; von Kriegsheim A; Freile P; Popplewell L; Dickson G; Murphy L; Wheeler A; Dunlop M; Din F; Strathdee D; Sansom OJ; Myant KB
Nat Commun; 2021 Apr; 12(1):2335. PubMed ID: 33879799
[TBL] [Abstract][Full Text] [Related]
2. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
3. RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer.
Goka ET; Chaturvedi P; Lopez DTM; Garza A; Lippman ME
Mol Cancer Ther; 2019 May; 18(5):957-968. PubMed ID: 30926638
[TBL] [Abstract][Full Text] [Related]
4. Activation of tumor-specific splice variant Rac1b by dishevelled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells.
Esufali S; Charames GS; Pethe VV; Buongiorno P; Bapat B
Cancer Res; 2007 Mar; 67(6):2469-79. PubMed ID: 17363564
[TBL] [Abstract][Full Text] [Related]
5. The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression.
Kotelevets L; Walker F; Mamadou G; Lehy T; Jordan P; Chastre E
Oncogene; 2018 Nov; 37(46):6054-6068. PubMed ID: 29985482
[TBL] [Abstract][Full Text] [Related]
6. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways.
Gonçalves V; Matos P; Jordan P
Hum Mol Genet; 2009 Oct; 18(19):3696-707. PubMed ID: 19602482
[TBL] [Abstract][Full Text] [Related]
8. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
9. Negative regulation of TGFβ-induced apoptosis by RAC1B enhances intestinal tumourigenesis.
Gudiño V; Cammareri P; Billard CV; Myant KB
Cell Death Dis; 2021 Sep; 12(10):873. PubMed ID: 34564693
[TBL] [Abstract][Full Text] [Related]
10. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
11. Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b.
Matos P; Kotelevets L; Goncalves V; Henriques AF; Henriques A; Zerbib P; Moyer MP; Chastre E; Jordan P
Neoplasia; 2013 Jan; 15(1):102-11. PubMed ID: 23359345
[TBL] [Abstract][Full Text] [Related]
12. Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells.
Matos P; Jordan P
J Biol Chem; 2006 May; 281(19):13724-13732. PubMed ID: 16551621
[TBL] [Abstract][Full Text] [Related]
13. Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
Andrijes R; Hejmadi RK; Pugh M; Rajesh S; Novitskaya V; Ibrahim M; Overduin M; Tselepis C; Middleton GW; Győrffy B; Beggs AD; Berditchevski F
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34521767
[TBL] [Abstract][Full Text] [Related]
14. Increased Rac1b expression sustains colorectal tumor cell survival.
Matos P; Jordan P
Mol Cancer Res; 2008 Jul; 6(7):1178-84. PubMed ID: 18644982
[TBL] [Abstract][Full Text] [Related]
15. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.
Gonçalves V; Henriques AF; Pereira JF; Neves Costa A; Moyer MP; Moita LF; Gama-Carvalho M; Matos P; Jordan P
RNA; 2014 Apr; 20(4):474-82. PubMed ID: 24550521
[TBL] [Abstract][Full Text] [Related]
17. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
18. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
19. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling.
Matos P; Collard JG; Jordan P
J Biol Chem; 2003 Dec; 278(50):50442-8. PubMed ID: 14506233
[TBL] [Abstract][Full Text] [Related]
20. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
